Hypertrophic cardiomyopathy (HCM) occurs in 1 in every 500 individuals. It represents the most common cause of sudden cardiac death in those under the age of twenty-five. 3-5% patients with HCM go on to develop the dilated, hypokinetic end stage (ES) HCM with systolic failure. They have a higher incidence of heart failure, sudden deaths and defibrillator shocks. To the best of our knowledge this is first report of successful use of dronedarone for suppression of VT associated with ES HCM.
Nanda, S., Levin, V., & Martinez, M. W. (2012). Ventricular tachycardia in "end stage" hypertrophic cardiomyopathy: a role of dronedarone. Minerva Cardioangiologica, 60(6), 637-642.